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Abstract
Background: Hip replacement surgery is increasingly common due to an ageing population, and rising levels of
obesity. The provision of excellent pain relief with minimal side effects is important in order to facilitate patient
mobilisation and rehabilitation.
Spinal opioids provide excellent analgesia but are associated with adverse effects. The fascia-iliaca block is an
alternative technique which provides analgesia to the nerves innervating the hip. The success of fascia iliaca blocks
has been demonstrated to be superior when using ultrasound compared to landmark techniques. However, the
clinical benefit of this improvement has yet to be investigated.
The aim of this study is to compare the efficacy and safety of ultrasound guided fascia iliaca block with spinal
morphine for hip replacement surgery.
Methods/Design: This study is a randomised, blinded, placebo-controlled, noninferiority trial. Patients scheduled to
undergo unilateral primary hip arthroplasty will receive a study information sheet and consent will be obtained in
keeping with the Declaration of Helsinki. Patients will be randomised to receive either; (i) Ultrasound guided fascia
iliaca block using levobupivacaine, plus spinal anaesthesia with hyperbaric bupivacaine containing no morphine, or
(ii) sham ultrasound guided fascia iliaca block performed with sterile saline, and spinal anaesthesia containing
hyperbaric bupivacaine and 0.1 mg of spinal morphine.
A total of 108 patients will be recruited. Primary outcome is post-operative morphine consumption in a 24 hour
period. Secondary outcomes include; pain scores at 3, 6, 12, 24, 36 and 48 hours, episodes of respiratory
depression, hypotension, nausea and vomiting, pruritus, sedation, time to first mobilisation and patient satisfaction.
Conclusions: There are no studies to date comparing ultrasound guided fascia iliaca block with spinal morphine
for pain control after hip arthroplasty. If the ultrasound guided fascia iliaca block provides pain relief which is not
inferior to spinal morphine, then morphine could be removed from the spinal injection. This could reduce side
effects and improve patient safety.
Trial registration: This study has been approved by the West of Scotland Research Ethics Committee 4 (reference
no. 10/S0704/43) and is registered with ClinicalTrials.gov (reference no. NCT01217294).
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Hip surgery is increasingly being performed, often in
elderly patients with significant co-morbidity [1]. Whilst
the optimal anaesthetic technique is yet to be estab-
lished [2], it is important that side effects are minimised
to optimise patient safety and comfort and to facilitate
rehabilitation. The main anaesthetic options are general
anaesthesia (GA) and regional anaesthesia (RA) or a
combination of the two. In a recent systematic review,
regional anaesthesia (RA) was demonstrated to reduce
post-operative pain, morphine consumption and nausea
and vomiting compared to systemic analgesia [3].
Spinal anaesthesia is a RA technique commonly used
in many patients undergoing hip arthroplasty [4].
Opioids are frequently added to the spinal anaesthetic in
order to prolong and improve post-operative pain relief
[5] and are associated with reduced post-operative mor-
phine requirements in patients undergoing hip arthro-
plasty [6-8]. However, intrathecal opioids are associated
with side effects including urinary retention, nausea and
vomiting, pruritus and rarely, but most seriously,
respiratory depression [9]. Such adverse effects can be
uncomfortable for the patient, delay mobilisation, recov-
ery and eventual discharge and occasionally be danger-
ous [10,11].
In patients undergoing hip arthroplasty peripheral
nerve blockade has been shown to improve pain scores
and reduce morphine consumption [3]. The fascia iliaca
nerve block can provide sensory blockade of the main
nerves which supply pain to the hip [12,13]. However,
clinical success rates of this block when performed
‘blindly’ using traditional landmark techniques are vari-
able [14]. Using ultrasound to locate nerves during per-
ipheral nerve blockade has repeatedly been shown to
increase success rates, reduce block onset time, increase
block duration, reduce volumes of local anaesthetic
required and increase patient satisfaction compared to
traditional techniques [15-21]. The use of ultrasound
guidance in the fascia iliaca plane block has been shown
to increase success compared with the landmark techni-
que [22]. In this study however, the clinical benefits of
this increased success were not investigated.
Ultrasound guided fascia iliaca block has not yet been
evaluated clinically as a method of providing post-opera-
tive analgesia following primary hip arthroplasty. We
hypothesise that by increasing the success rate of the
fascia iliaca block with ultrasound, it will be possible to
achieve superior and more reliable analgesia than that
obtained using the landmark based technique. The aim
of this study is to assess whether the ultrasound guided
fascia iliaca plane block can provide comparable post-
operative analgesia to spinal morphine for primary hip
arthroplasty. If this is the case, spinal opioid could be
removed from the spinal anaesthetic. This could poten-
tially reduce troublesome opioid related side effects and
have significant safety benefits. The further investigation
of this technique will provide a valuable contribution to
existing knowledge, and could profoundly change cur-
rent practice.
Methods/Design
Overview
This is a single centre, randomised, blinded, placebo-
controlled, non-inferiority study [23]. This study has
been approved by the West of Scotland Research Ethics
Committee 4 (reference no. 10/S0704/43) and is regis-
tered with the ClinicalTrials.gov database (reference no.
NCT01217294). This study will be performed in keeping
with the requirements of the Declaration of Helsinki.
Hypothesis
Ultrasound guided fascia iliaca plane block provides
post-operative analgesia which is not inferior to that
obtained with spinal morphine in patients undergoing
primary hip arthroplasty.
Objectives and Outcome Measures
This study aims to compare the efficacy and safety of
ultrasound guided fasca iliaca block with intrathecal
morphine in the provision of post-operative analgesia
after primary hip arthroplasty. The primary outcome
measure is post-operative morphine consumption in a
24 hour period as self administered using a patient con-
trolled analgesia (PCA) pump. Secondary outcomes
include pain scores at 3, 6, 12, 24, 36 and 48 hours,
time to 1st morphine administration, episodes of
respiratory depression, hypotension, nausea and vomit-
ing scores, pruritus scores, sedation scores, urinary
retention, time to first mobilisation and patient
satisfaction.
Study centre
Our centre is a tertiary referral facility for orthopaedics
and trauma surgery with the necessary type and volume
of clinical cases required for this study. There is a
wealth of experience on the use of ultrasound guidance
for regional anaesthetic techniques, including fascia
iliaca block [22], within the department.
Patients and enrolment
Patients scheduled to undergo unilateral primary hip
arthroplasty will be invited to participate in the study
during their routine pre-assessment visit two weeks
prior to the date of surgery. Inclusion criteria are; ASA
physical status I - III, 18 - 85 years of age, weight
b e t w e e n5 0-1 1 0k g ,a n dc o m p e t e n c et oc o n s e n t .
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plane block or spinal anaesthesia such as coagulopathy,
malignancy or infection in the inguinal area, preference
for general anaesthesia, allergy to opioids, significant
peripheral neuropathy or neurological disorder affecting
the lower extremity, pregnancy, history of alcohol or
drug dependency, history of long term strong opioid
intake (i.e. WHO step 3 analgesics), and history of sig-
nificant psychiatric conditions that may affect patient
assessment.
All suitable patients will be given a patient informa-
tion sheet approved by the West of Scotland Ethics
Committee. They will be given an opportunity to review
this before written informed consent is obtained prior
to surgery.
Consent
The process of consent will be in accordance with the
Declaration of Helsinki. Patients will be fully informed
that they are being asked to participate in a research
study. The procedures involved in the study, and the
chances of being assigned randomly to one of two
groups will be explained in person and via an informa-
tion sheet. A signed, consent form will be obtained from
each patient and retained by the investigators. Patients
will be made aware of their right to withdraw from the
study at any time without adverse effects on their clini-
cal care.
Randomisation
A computer generated allocation sequence (in permuted
blocks) will be created by an independent operator who
is not directly involved with the study. Once created,
the allocation sequence will be kept in a secure locked
drawer making it inaccessible to all study personnel.
Allocation concealment will be achieved using sequen-
tially numbered sealed envelopes which are opaque
when held to the light. When a patient is enrolled in
the study, an administrator working within the Glasgow
University Academic Unit of Anaesthesia will be con-
tacted and asked to give the next numbered envelope to
the anaesthetist who will make up the medications used
in the study. The administrator will record the patient’s
details and the number of the envelope assigned to that
patient. The allocation sequence will be accessed only
when study data collection is complete or in any
instance where unblinding of the study is thought to be
essential in the provision of appropriate patient care.
Patients in the Fascia Iliaca Group will receive; spinal
anaesthesia with hyperbaric bupivacaine at a dose
between 10 and 15 mg, adjusted based on patient height
and weight at the discretion of the attending anaesthe-
tist, with no spinal morphine (0.1 ml sterile saline will
be administered in its place). Ultrasound guided fascia
iliaca block using 2 mg/kg levobupivacaine diluted to a
total of 40 ml with sterile saline.
Post-operative analgesia will include Paracetamol 1 g
four times daily and patient controlled analgesia (PCA)
with morphine (1 mg bolus, 5 minute lockout period).
Patients in the Spinal Morphine Group will receive;
spinal anaesthesia with hyperbaric bupivacaine as above,
and with the addition of intrathecal morphine 100
micrograms (0.1 ml). “Sham” ultrasound guided fascia
iliaca injection with 40 ml of sterile saline. Post-opera-
tive analgesia in the same manner as in the Fascia Iliaca
Group.
Blinding
The ultrasound guided fascia iliaca block will be per-
formed by an anaesthetist deemed competent in this
technique. The injectate solutions will have been pre-
prepared in an aseptic manner by a separate anaesthetist
not involved with post-operative data collection or ana-
lysis. In this way, the investigator performing the ultra-
sound guided fascia iliaca block and spinal injections
will be blinded to the nature of the injectates. As
patients will receive both spinal and ultrasound guided
fascia iliaca injections, they will also be blinded. Data
will be anonymised and collected by an investigator who
is blinded to the patient’s allocation.
Intra-operative management
The anaesthetist looking after the patient in theatre will
play no part in data analysis and will record the intra-
operative proceedings as normal. The patient’s participa-
tion in this study and the 2 possible anaesthetics that may
have been administered will be documented on the anaes-
thetic chart. The randomisation code may be accessed if
deemed necessary in the provision of optimal patient care.
The patient may receive sedation if requested and as direc-
ted by the anaesthetic doctor. Fluid administration and the
use of vasopressors will again be at the discretion of the
anaesthetic doctor. All medications, with the exception of
the medications used to perform the spinal or fascia iliaca
block, will be detailed in the anaesthetic record. No anti-
emetic will be administered peri-operatively unless specifi-
cally indicated.
Postoperative management
After surgery, patients will be taken to the recovery
room and monitored according to standard hospital pol-
icy. Pain will be treated, if required, with intravenous
morphine every 5 - 10 min as directed by nursing staff.
Patients will be familiarised with the Patient Controlled
Analagesia (PCA) device and discharged once recovery
room discharge criteria have been met. Patients will
remain on oxygen for at least 24 hours and whilst
receiving PCA morphine as is routine in our unit.
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depression as specified on the PCA protocol.
After a 48 hour period, data regarding pain scores,
nausea, itch, sedation and hypotension will cease being
collected as detailed in the primary and secondary out-
comes. The investigator who collects the data will be
blinded as to the nature of the anaesthetic administered.
The time to first mobilisation will be assessed and the
patient will continue to be monitored by physiotherapy
staff until discharge. Any serious adverse events will
prompt follow up. Patients will be seen routinely at
6 weeks following discharge by the arthroplasty specia-
list nurse. Symptoms of nerve damage will be actively
sought at this consultation. Patients will be asked to rate
their level of satisfaction with post-operative analgesia at
both 48 hour and 6 week time points.
Criteria for discontinuation
Every effort will be made to retain patients in the trial
and to minimise withdrawals. Patients may request to
be withdrawn from this study at any time. Intention to
treat and “as treated” analyses will be performed.
Data Collection
Data will be obtained from copies of the anaesthetic
record, recovery room observation chart, PCA chart,
ward observation chart and drug prescription chart.
T h e s ec h a r t sw i l lb er e v i e w e da f t e rt h ef i r s t4 8h o u r
post-operative period by a member of the research
team. The researcher will be blinded to the anaesthetic
technique used. All documentation relating to the study
will be stored in an anonymised case report file unique
to each patient. These case report files will be archived
in a locked facility for a period of 10 years.
Sample Size and Statistical Considerations
In the comparison of ultrasound guided fascia iliaca
block with spinal opioid in patients undergoing primary
hip replacement, we intend to compare an established
technique in widespread practice (spinal morphine) with
the less well investigated technique of ultrasound guided
fascia iliaca block. The primary outcome of the study is
24 hour morphine consumption. This outcome is used
commonly in trials of spinal opioid for hip arthroplasty
surgery. Mean 24 hour morphine consumption after hip
arthroplasty is reported to lie within the range 10 mg
[6] to 30 mg [7] when using 0.1 mg intrathecal mor-
phine. From our own audit data of patients receiving
spinal opioid for hip arthroplasty over an 8 month per-
iod, mean 24 hour post-operative morphine consump-
tion was 24.6 (SD 17.6) mg which lies within the
reported range described above [6,7].
In order to calculate sample size, we used a method
suggested for non-inferiority trials [23,24]. For this we
made the following assumptions. Type 1 error (a)w a s
set at 0.05; Type 2 error (b) at 0.8; and Z numbers
b a s e do no n e - t a i l e dt e s t i n g .W ec o n s i d e r e dad i f f e r -
ence between groups (δ*) of greater than 10 mg of
morphine to be clinically significant. 10 mg of mor-
phine equates to one subcutaneous dose of morphine
commonly used in post-operative analgesia pain
protocols [25].
The expected difference between the Control (spinal
morphine) and Treatment (ultrasound guided fascia
iliaca) groups (δ) is more difficult to estimate. To date,
there is only one published trial looking at 24 hour
post-operative morphine consumption after fascia iliaca
block for hip arthroplasty, although this was performed
with the landmark technique alone and did not employ
ultrasound [13]. In this study, mean 24 hour post-
operative morphine consumption in the fascia iliaca
group was 23 mg. Therefore, there is a 1.6 mg difference
between the mean 24 hour morphine consumption
obtained from our audit data of patients receiving spinal
morphine, and that obtained in a study looking at
patients receiving fascia iliaca block for hip arthroplasty
[13]. Thus, the number of patients required to ade-
quately power this study is 108.
The null Hypothesis (H0) for this non-inferiority study
is that the experimental treatment (ultrasound guided
fascia iliaca block) is in fact inferior to the established
treatment (spinal morphine) by more than the clinically
significant amount (δ*). If H0 is rejected, the alternative
hypothesis is that ultrasound guided fascia iliaca block is
not inferior to IT opioid.
The study will be performed using both intention to
treat and “as treated” analyses. In the intention to treat
analysis, patients will be considered failures if they
require general anaesthesia, or were unable to receive
randomised treatment for any other reason. In the “as
treated” analysis, only data from patients completing
randomised treatment will be analysed.
Secondary data analyses will be carried out on all sec-
ondary outcomes. These will be compared between
groups using t-test, and Mann-Whitney, or Chi-squared
tests as appropriate.
It is anticipated that recruitment for this study will
take between 12 and 18 months to complete if 1 to 2
patients are enrolled each week, using one surgeon to
reduce surgical variability. Data collection for each
patient will occur during the first 48 hours post-opera-
tively and at a routine 6 week follow up appointment.
No further follow up will be routinely arranged. Any
patients requiring specific follow up will have this
arranged on an individual basis.
We recognise that while this study is powered for the
primary outcome, it is not powered for the secondary
outcomes. However, the data we collect in this study
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ing specifically at these outcomes.
Adverse Event Reporting and Safety
All adverse events will be recorded and discussed at
monthly safety meetings by at least 2 investigators. If
clinically indicated, the nature of the anaesthetic admi-
nistered in the study may be revealed. After assessment
by the Principle Investigator, any serious adverse events
(SAEs) and suspected unexpected serious adverse reac-
tions (SUSARs) will be reported to the Pharmacovigi-
lance Office in the Robertson Centre for Biostatistics in
Glasgow. All SUSARs will be reported to the Medicines
and Healthcare products Regulatory Agency (MHRA) by
the Pharmacovigilance Office at the Robertson Centre
for Biostatistics in Glasgow.
Discussion
Risk Benefit Assessment
We expect that all patients will benefit from this study
in view of the high level of post-operative monitoring
and follow up which will be employed. In order to
achieve blinding and improve the validity of the study, a
“sham” ultrasound guided fascia iliaca block will be per-
formed in patients in the Spinal Morphine Group. These
patients will therefore receive an injection of an inactive
substance (sterile saline) into the groin. As no local
anaesthetic is being used in the sham block, potential
risks will include; discomfort on injection, bleeding or
b r u i s i n ga tt h ep u n c t u r es i t ea n dn e r v ed a m a g e .N e r v e
damage is rare with fascia iliaca blocks as the needle is
not directed towards the nerves themselves, but rather
to lie in a plane between muscle layers. In the patients
receiving fascia iliaca block with local anaesthetic, the
risks are as before with the addition of local anaesthetic
toxicity, although a pre-determined safe dose of local
anaesthetic is being used.
Patients in the Spinal Morphine Group will receive
intrathecal morphine. Spinal opioids have been used
since 1979 to provide pain control after surgery [26]. Due
to its widespread international use, intrathecal morphine
has been extensively investigated in this setting and
spinal morphine in combination with systemic morphine
i sac o m m o n l yu s e dp o s t - o p e r a t i v er e g i m ef o rm a n ys u r -
gical procedures including hip arthroplasty [27-29]. Low
dose intrathecal morphine can provide adequate analge-
sia whilst minimising side-effects [6-8]. Such side-effects
include; delayed respiratory depression, pruritus, post-
operative nausea and vomiting and urinary retention
[5,30-32]. Although respiratory depression is rare with
low doses of intrathecal morphine, [33] it is potentially
life-threatening. Furthermore, the concomitant use of
systemic opioids for post-operative analgesia may add to
this risk. Previous research has concluded that 100
micrograms of intrathecal morphine combines analgesic
efficacy whilst minimising the side effect profile [6,8].
Reassuringly, in a dose-finding study of intrathecal mor-
phine for hip and knee surgery, there was no increased
incidence of respiratory depression or hypoxaemia in
patients receiving up to 0.3 mg of intrathecal morphine.
This included elderly patients who had also received “sig-
nificant doses of PCA morphine” [7].
A recent meta-analysis of 1300 patients was unable to
define whether the use of intrathecal morphine
increased the risk of respiratory depression [33]. Studies
investigating the use of intrathecal opioid are generally
not adequately powered to detect the incidence of
respiratory depression. However, it is believed that
lower doses result in a reduced risk [6-8,28,33,34].
A recent trial of 1915 patients receiving 0.15 mg of
intrathecal morphine for Caesarean section found the
incidence of a respiratory rate of less than 10 breaths
per minute to be 0.26% and the need for naloxone
0.052% [34]. However, there is no evidence that there is
an effective dose of intrathecal morphine that would
completely preclude the occurrence of respiratory
depression. An accurate estimate of the incidence of this
complication would therefore require a trial containing
very large numbers of patients and is impractical to
undertake. In keeping with other investigators, we can
not accurately predict the incidence of respiratory
depression that may occur after the use of low dose
intrathecal opioid and PCA morphine.
In the planning of this study, a number of measures
have been employed to reduce this potential risk. These
include; the utilisation of the lowest possible effective
dose of intrathecal morphine (0.1 mg), the use of speci-
fic monitoring charts to ensure that the patient is moni-
tored on an hourly basis, delivery of supplemental
oxygen whilst receiving morphine via the PCA device,
and the use of clear protocols to be followed by nursing
staff in the management of adverse events. All nursing
staff involved in post-operative patient care are compe-
tent and experienced in the management of patients
who have received intrathecal and systemic morphine,
and are trained in the necessary monitoring procedures.
Both spinal anaesthesia and peripheral nerve blockade
are commonly performed for hip arthroplasty in the
United Kingdom. Any possible risks must be weighed up
against the risks of a general anaesthetic. Any adverse
events relating to each of the procedures will be recorded
by staff performing the study and any necessary investi-
gations, treatment or follow up arranged thereafter.
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